CCR5 and neoplasm: We have also contributed to this notion recently and showed that targeting CCR5 by an FDA-approved antagonist (maraviroc) induces anti-cancer effects and inhibits the tumor growth in vivo (Huang et al. 2020; Pervaiz et al. 2015, 2019).